Attorney Docket No.: Q85416

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (original): A tetrahydroquinoline derivative represented by the following formula (I) or pharmacologically acceptable salts thereof:

wherein R¹ represents a nitro group or a cyano group;

X represents CH or O, provided that when X is CH, the dashed line represents a double bond;

m represents 0 or 1;

Y represents an alkylene group having 1 - 5 carbon atoms which may be substituted by a substituent selected from the group consisting of an alkyl group having 1 - 5 carbon atoms and a cycloalkyl group having 3 - 7 carbon atoms;

R² represents a hydrogen atom, an alkyl group having 1 - 5 carbon atoms, a cycloalkyl group having 3 - 7 carbon atoms or an aralkyl group having 7 - 9 carbon atoms;

Z represents -B-O-Q

[wherein B represents an alkylene group having 1 - 5 carbon atoms which may be substituted by a substituent selected from the group consisting of an alkyl group having 1 - 5

Application No.: 10/518,405

Attorney Docket No.: Q85416

carbon atoms and a cycloalkyl group having 3-7 carbon atoms; Q is a hydrogen atom, an alkyl group having 1-5 carbon atoms or a cycloalkyl group having 3-7 carbon atoms which may be substituted by a substituent selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group and an alkoxy group having 1-5 carbon atoms, or an aryl group, a heteroaryl group or an aralkyl group having 7-9 carbon atoms which may have a substituent R^3 ,

R³ represents an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom, a halogen atom, an aryl group, a heteroaryl group, a nitro group, a cyano group, - A-R4 {wherein A represents -CO-, -CO₂-, -COS-, -CONR⁵-, -O-, -OCO-, -OSO₂-, -S-, SCO-, -SO-, -SO₂-, -NR⁵CO-, -NR⁵SO₂-, -NR⁵CONH-, NR⁵CSNH- or -NR⁵COO- (wherein R⁵ represents a hydrogen atom, an alkyl group having 1 - 5 carbon atoms, a cycloalkyl group having 3 - 7 carbon atoms or an aralkyl group having 7 - 9 carbon atoms),

R⁴ is a hydrogen atom, an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom, a cycloalkyl group having 3 - 7 carbon atoms, a halogen atom, or an aryl group or a heteroaryl group which may be substituted by R⁶ (wherein R⁶ represents an alkyl group having 1 - 5 carbon atoms, an alkoxy group having 1 - 5 carbon atoms or a halogen atom), provided that when A is NR⁵- or -CONR⁵-, R⁴ and R⁵ may, together with the nitrogen atom to which they are bonded, form pyrrolidine or piperidine)}, or -A'-(CH₂)_n-R⁴' {wherein A' represents a single bond, -CO-, -CO₂-, -COS-, -CONR⁵'-, -O-, -OCO-, -OSO₂-, -S-, SCO-, -SO-, -SO₂-, -NR⁵'-, -NR⁵'CO-, -NR⁵'SO₂-, -NR⁵'CONH-, NR⁵'CSNH- or -NR⁵'COO- (wherein R⁵' represents a hydrogen atom, an alkyl group having 1 - 5 carbon atoms, a cycloalkyl group having 3 - 7 carbon atoms or an aralkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom, a cycloalkyl group having 3 - 7 carbon atoms, a halogen atom, a

Application No.: 10/518,405

hydroxyl group, a cyano group, an alkoxy group having 1 - 5 carbon atoms, an alkylacyloxy group having 2 - 5 carbon atoms, an alkoxycarbonyl group having 2 - 5 carbon atoms, an aryl group or a heteroaryl group which may be substituted by R⁶¹ (wherein R⁶¹ represents an alkyl group having 1 - 5 carbon atoms, an alkoxy group having 1 - 5 carbon atoms or a halogen atom), or -NR⁷¹R⁸¹ (wherein R⁷¹ and R⁸¹ each independently have the same meaning as the aforementioned R⁵¹, provided that R⁷¹ and R⁸¹ may, together with the nitrogen atom to which they are bonded, form pyrrolidine or piperidine), provided that when A' is -NR⁵¹- or -CONR⁵¹-, R⁴¹ and R⁵¹ may, together with the -N-(CH₂)_n- to which they are bonded, form pyrrolidine or piperidine}], or alternatively Z represents -(CH₂)_r-W

Attorney Docket No.: Q85416

[wherein r represents an integer of 0 - 2, W represents

a phenyl group having substituent R^9 at p-position, a naphthyl group which may have substituent R^{10} or a heteroaryl group which may be substituted by 1 - 3 independent R^{11} 's (wherein R^9 , R^{10} and R^{11} independently have the same meaning as the aforementioned R^3)].

- **2.** (withdrawn): The tetrahydroquinoline derivative according to claim 1, where Y is -CH(CH₃)-CH₂- or -C(CH₃)₂-CH₂-, X is CH, m is 0, R² is a hydrogen atom and Z is -CH₂-O-Q (wherein Q represents an alkyl group having 1 5 carbon atoms) or pharmacologically acceptable salts thereof.
- **3. (original):** The tetrahydroquinoline derivative according to claim 1, where Y is $CH(CH_3)$ - CH_2 or - $C(CH_3)_2$ - CH_2 -, m is 0, R^2 is a hydrogen atom and Z is -W [wherein W is a heteroaryl group which may be substituted by 1 3 independent R^{11} 's or a phenyl group having substituent R^9 at p-position {wherein R^{11} and R^9 independently represent a halogen atom, an

Application No.: 10/518,405

alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom, a nitro group, a cyano group, -A-R⁴ (wherein A is -CO-, -CO₂-, -O-, -NHCO- or -NHCONH-, and R⁴ is a hydrogen atom or an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom) or -A'-(CH₂)n-R⁴ (wherein A' is -CO-, -CO₂-, -O-, -NHCO- or -NHCONH-, R⁴ is a hydrogen atom, an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom, a hydroxyl group, a halogen atom or an alkoxy group having 1 - 5 carbon atoms, and n is an integer of 1 or 2)}] or pharmacologically acceptable salts thereof.

Attorney Docket No.: Q85416

- **4. (original):** The tetrahydroquinoline derivative according to claim 3, where Z is a phenyl group having substituent R⁹ at p-position or a heteroaryl group having substituent R¹¹ {wherein R⁹ and R¹¹ independently represent a halogen atom, -O-R⁴ or -NHCO-R⁴ (wherein R⁴ represents a hydrogen atom or an alkyl group having 1 5 carbon atoms which may be substituted by a fluorine atom)} or pharmacologically acceptable salts thereof.
- **5. (original):** The tetrahydroquinoline derivative according to claim 3, where Z is a phenyl group having substituent R⁹ at p-position or a heteroaryl group having substituent R¹¹ {wherein R⁹ and R¹¹ represent -NHCO-R⁴ (wherein R⁴ represents a hydrogen atom or an alkyl group having 1 5 carbon atoms which may be substituted by a fluorine atom)} or pharmacologically acceptable salts thereof.
- 6. (currently amended): A pharmaceutical comprising the The tetrahydroquinoline derivative or pharmacologically acceptable salts thereof according to any one of claims 1 and 3 to 5 as an active ingredient and a pharmaceutically acceptable carrier or excipient.

Application No.: 10/518,405

Attorney Docket No.: Q85416

alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom, a nitro group, a cyano group, -A-R⁴ (wherein A is -CO-, -CO₂-, -O-, -NHCO- or -NHCONH-, and R⁴ is a hydrogen atom or an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom) or -A'-(CH₂)n-R⁴ (wherein A' is -CO-, -CO₂-, -O-, -NHCO- or -NHCONH-, R⁴ is a hydrogen atom, an alkyl group having 1 - 5 carbon atoms which may be substituted by a fluorine atom, a hydroxyl group, a halogen atom or an alkoxy group having 1 - 5 carbon atoms, and n is an integer of 1 or 2)}] or pharmacologically acceptable salts thereof.

- **4. (original):** The tetrahydroquinoline derivative according to claim 3, where Z is a phenyl group having substituent R⁹ at p-position or a heteroaryl group having substituent R¹¹ {wherein R⁹ and R¹¹ independently represent a halogen atom, -O-R⁴ or -NHCO-R⁴ (wherein R⁴ represents a hydrogen atom or an alkyl group having 1 5 carbon atoms which may be substituted by a fluorine atom)} or pharmacologically acceptable salts thereof.
- **5. (original):** The tetrahydroquinoline derivative according to claim 3, where Z is a phenyl group having substituent R⁹ at p-position or a heteroaryl group having substituent R¹¹ {wherein R⁹ and R¹¹ represent -NHCO-R⁴ (wherein R⁴ represents a hydrogen atom or an alkyl group having 1 5 carbon atoms which may be substituted by a fluorine atom)} or pharmacologically acceptable salts thereof.
- 6. (currently amended): A pharmaceutical comprising the The tetrahydroquinoline derivative or pharmacologically acceptable salts thereof according to any one of claims 1 and 3 to 5 as an active ingredient and a pharmaceutically acceptable carrier or excipient.

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q85416

Application No.: 10/518,405

7. - 10. (canceled).

11. (currently amended): A method of preventing or treating muscle wasting disease

or osteoporosis, which comprises administering to a mammal in need of such prevention or

treatment, the tetrahydroquinoline derivative or pharmacologically acceptable salts thereof

according to any one of claims 1 and 3 to 5 in an amount effective to prevent or treat said those

diseases.

12. (currently amended): A method of preventing or treating a disease selected from

the group consisting of male hypogonadism, male sexual dysfunction, abnormal sex

differentiation, male delayed puberty, cancer in female genital organ, breast cancer, mastopathy,

endometriosis and female sexual dysfunction, which comprises administering to a mammal in

need of such prevention or treatment, the tetrahydroquinoline derivative or pharmacologically

acceptable salts thereof according to any one of claims 1 and 3 to 5 in an amount effective to

prevent or treat said those diseases.

13. (canceled):

6